You may know about tirzepatide, also known as Mounjaro or Zepbound, due to its popularity for those looking to lose weight or treat diabetes. Now, researchers have gotten it approved to treat sleep ...

Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Zepbound (tirzepatide) is a prescription drug used to help with weight loss, weight management, and obstructive sleep apnea (OSA) in some adults. It works by mimicking the action of certain ...

Zepbound is also approved to treat severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound can cause mild to serious side effects, but insomnia is not among the side effects reported ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

This review included 30 studies to analyze the potential for prolonged life in patients who use CPAP to treat obstructive sleep apnea.